In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A chain immunotoxins

K. A. Krolick, J. W. Uhr, S. Slavin, E. S. Vitetta

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Prolonged remissions were induced in mice bearing advanced BCL1 tumors by the combined approach of nonspecific cytoreductive therapy and administration of a tumor-reactive immunotoxin. Thus, the vast majority of the tumor cells (~95%) were first killed by nonspecific cytoreductive therapy using total lymphoid irradiation (TLI) and splenectomy. The residual tumor cells were then eliminated by intravenous administration of an anti-δ immunotoxin. In three of four experiments, all animals treated in the above fashion appeared tumor free 12-16 wk later. In one experiment, blood cells from the mice in remission were transferred to normal BALB/c recipients, and the latter animals have not developed detectable tumor for the 6 mo of observation. Because 1-10 adoptively transferred BCL1 cells will cause tumor in normal BALB/c mice by 12 wk, the inability to transfer tumor to recipients might indicate that the donor animals were tumor free. In the remainder of the animals treated with the tumor-reactive immunotoxin there was a substantial remission in all animals, but the disease eventually reappeared. In contrast, all mice treated with the control immunotoxin or antibody alone relapsed significantly earlier (3-4 wk after splenectomy).

Original languageEnglish (US)
Pages (from-to)1797-1809
Number of pages13
JournalJournal of Experimental Medicine
Volume155
Issue number6
StatePublished - 1982

Fingerprint

Ricin
Immunotoxins
B-Lymphocytes
Antibodies
Neoplasms
Therapeutics
Splenectomy
Lymphatic Irradiation
Animal Diseases
Residual Neoplasm
Intravenous Administration
Blood Cells
Observation

ASJC Scopus subject areas

  • Immunology

Cite this

In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A chain immunotoxins. / Krolick, K. A.; Uhr, J. W.; Slavin, S.; Vitetta, E. S.

In: Journal of Experimental Medicine, Vol. 155, No. 6, 1982, p. 1797-1809.

Research output: Contribution to journalArticle

@article{1dbaab083f30496d8b54ad9561eb7351,
title = "In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A chain immunotoxins",
abstract = "Prolonged remissions were induced in mice bearing advanced BCL1 tumors by the combined approach of nonspecific cytoreductive therapy and administration of a tumor-reactive immunotoxin. Thus, the vast majority of the tumor cells (~95{\%}) were first killed by nonspecific cytoreductive therapy using total lymphoid irradiation (TLI) and splenectomy. The residual tumor cells were then eliminated by intravenous administration of an anti-δ immunotoxin. In three of four experiments, all animals treated in the above fashion appeared tumor free 12-16 wk later. In one experiment, blood cells from the mice in remission were transferred to normal BALB/c recipients, and the latter animals have not developed detectable tumor for the 6 mo of observation. Because 1-10 adoptively transferred BCL1 cells will cause tumor in normal BALB/c mice by 12 wk, the inability to transfer tumor to recipients might indicate that the donor animals were tumor free. In the remainder of the animals treated with the tumor-reactive immunotoxin there was a substantial remission in all animals, but the disease eventually reappeared. In contrast, all mice treated with the control immunotoxin or antibody alone relapsed significantly earlier (3-4 wk after splenectomy).",
author = "Krolick, {K. A.} and Uhr, {J. W.} and S. Slavin and Vitetta, {E. S.}",
year = "1982",
language = "English (US)",
volume = "155",
pages = "1797--1809",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "6",

}

TY - JOUR

T1 - In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A chain immunotoxins

AU - Krolick, K. A.

AU - Uhr, J. W.

AU - Slavin, S.

AU - Vitetta, E. S.

PY - 1982

Y1 - 1982

N2 - Prolonged remissions were induced in mice bearing advanced BCL1 tumors by the combined approach of nonspecific cytoreductive therapy and administration of a tumor-reactive immunotoxin. Thus, the vast majority of the tumor cells (~95%) were first killed by nonspecific cytoreductive therapy using total lymphoid irradiation (TLI) and splenectomy. The residual tumor cells were then eliminated by intravenous administration of an anti-δ immunotoxin. In three of four experiments, all animals treated in the above fashion appeared tumor free 12-16 wk later. In one experiment, blood cells from the mice in remission were transferred to normal BALB/c recipients, and the latter animals have not developed detectable tumor for the 6 mo of observation. Because 1-10 adoptively transferred BCL1 cells will cause tumor in normal BALB/c mice by 12 wk, the inability to transfer tumor to recipients might indicate that the donor animals were tumor free. In the remainder of the animals treated with the tumor-reactive immunotoxin there was a substantial remission in all animals, but the disease eventually reappeared. In contrast, all mice treated with the control immunotoxin or antibody alone relapsed significantly earlier (3-4 wk after splenectomy).

AB - Prolonged remissions were induced in mice bearing advanced BCL1 tumors by the combined approach of nonspecific cytoreductive therapy and administration of a tumor-reactive immunotoxin. Thus, the vast majority of the tumor cells (~95%) were first killed by nonspecific cytoreductive therapy using total lymphoid irradiation (TLI) and splenectomy. The residual tumor cells were then eliminated by intravenous administration of an anti-δ immunotoxin. In three of four experiments, all animals treated in the above fashion appeared tumor free 12-16 wk later. In one experiment, blood cells from the mice in remission were transferred to normal BALB/c recipients, and the latter animals have not developed detectable tumor for the 6 mo of observation. Because 1-10 adoptively transferred BCL1 cells will cause tumor in normal BALB/c mice by 12 wk, the inability to transfer tumor to recipients might indicate that the donor animals were tumor free. In the remainder of the animals treated with the tumor-reactive immunotoxin there was a substantial remission in all animals, but the disease eventually reappeared. In contrast, all mice treated with the control immunotoxin or antibody alone relapsed significantly earlier (3-4 wk after splenectomy).

UR - http://www.scopus.com/inward/record.url?scp=0019954256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019954256&partnerID=8YFLogxK

M3 - Article

C2 - 6804591

AN - SCOPUS:0019954256

VL - 155

SP - 1797

EP - 1809

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 6

ER -